Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women-Reference-Cited by-同舟云学术

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Published:2008-01-23 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wells George A¹,Cranney Ann²,Peterson Joan³,Boucher Michel⁴,Shea Beverley⁵,Welch Vivian⁶,Coyle Doug⁷,Tugwell Peter⁸

Affiliation:

1. University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7

2. Ottawa Hospital; Division of Rheumatology; 1053 Carling Ave Ottawa Ontario Canada K1Y 4E9

3. Ottawa Civic Hospital / Loeb Research Institute; Clinical Epidemiology Unit; 1053 Carling Avenue Ottawa Ontario Canada K1Y 4E9

4. HTA Development Canadian Agency for Drugs and Technologies in Health (CADTH); 865 Carling Ave Suite 600 Ottawa Ontario Canada K1S 5S8

5. University of Ottawa; Institute of Population Health; 1 Stewart St. Room 312 Ottawa Ontario Canada K1N 6N5

6. University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street, Room 206 Ottawa Ontario Canada K1N 6N5

7. Ottawa Health Research Institute; Epidemiology and Community Medicine; 451 Smyth Rd. Ottawa Ontario Canada K1H 8M5

8. Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD004523.pub3/fullpdf

Reference71 articles.

1. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis;Clemmesen;Osteoporosis International,1997

2. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group;Fogelman;Journal of Clinical Endocrinology & Metabolism,2000

3. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group;Harris;JAMA,1999

4. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial;Hooper;Climacteric,2005

5. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.[see comment];McClung;New England Journal of Medicine,2001

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osteoporosis Update: Screening and Treatment Recommendations;Journal of Women's Health;2023-12-14

2. Effects of bisphosphonates and treadmill exercise on bone and kidney in adenine-induced chronic kidney disease rats;Journal of Bone and Mineral Metabolism;2023-10-28

3. Bisphosphonates for postmenopausal osteoporosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-09-28

4. Fracture risk after deprescription of bisphosphonates: Application of real-world data in primary care;Atención Primaria;2023-07

5. New insights into the role of long non-coding RNAs in osteoporosis;European Journal of Pharmacology;2023-07